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INCORPORATING EQUITY INTO DEVELOPING AND IMPLEMENTING EVIDENCE-
BASED CLINICAL PRACTICE GUIDELINES
Eslava-Schmalbach JH, Sandoval Vargas G, Mosquera PA
Universidad Nacional de Colombia, Bogotá, Colombia
BACKGROUND: Clinical practice guidelines (CPG) are useful tools for clinical deci-
sion making, processes standardization and quality of care improvements. The
current General Social Security and Health System (GSSHS) in Colombia is promot-
ing the initiative of developing and implementing CPG based on evidence in order
to improve efficiency and quality of care. The reduction of inequalities in health
should be an objective of the GSSHS. OBJECTIVES: The main propose of this anal-
ysis is to argue why it is necessary to consider the incorporation of equity consid-
erations in the development and implementation of clinical practice guidelines
based on the evidence. METHODS: A series of reflections were made. Narrative
description was used for showing the arguments that support the main findings.
RESULTS: Among the main findings are: 1) Differential effectiveness by social
groups of interventions could diminish final effectiveness of CPG in the GSSHS; 2)
To not consider geographical, ethnic, socioeconomic, cultural and access diversity
issues within the CPG could have a potential negative impacts of the CPG; 3) Overall
effectiveness of GPC could be better if equity issues are included in the quality
verification checklist of the guideline questions; and 4) Incorporating equity issues
in the process of developing CPG could be cost effective, because improve overall
effectiveness of CPG. CONCLUSIONS: To include equity issues in CPG and can help
in achieving more equitable health outcomes. From this point of view CPG could be
key tools to promote equity in care and health outcomes. Keywords: health in-
equalities, clinical practice guidelines, essay (Source: MeSH, NLM).
PRM6
TRANSLATION OF PATIENT-REPORTED OUTCOMES MEASURES
TRANSLATABILITY REVIEW AND ITEM DEFINITION
Arnold BJ1, Correia H2, Pérez B1, Lent L1
1FACITtrans, Elmhurst, IL, USA, 2Northwestern University, Chicago, IL, USA
Translatability Review and Item Definition documents are key components to any
successful Patient Reported Outcome (PRO) translation and are especially relevant
in item banking initiatives. Translatability review helps to ensure concepts, con-
structs and phrasing in the source language are appropriate for translation into
other languages and for multicultural contexts. Identifying potential issues during
item development can result in improvement of the source item. When modifica-
tion of the source is not possible or necessary, translatability review can be seen as
a first step towards identifying acceptable translation alternatives which can be
used by linguists. The assessment of item translatability before the translation
process begins also facilitates the creation of item definitions, a critical tool for
increasing translation accuracy. The Item Definition document refers to the iden-
tification and clarification of concepts the items are trying to measure. The devel-
opment of item definitions is an iterative process combining efforts by translation
coordinators and item/questionnaire developers as well as input from linguists.
These steps are especially essential in item banking initiatives in which items are
frequently made available by different developers and sources on behalf of varying
patient populations, with disparate answer categories. As translation of PRO mea-
sures is much more than just a literal, word for word translation process, these
steps are fundamental in furthering the equivalence, comparability and data
poolability of translated language versions. This presentation will provide infor-
mation regarding when to carry out these steps, how to carry them out and who
should be involved in them. Linguistic issues such as, but not limited to, sentence
structure, register and ambiguity will be discussed. Examples from National Insti-
tutes of Health Spanish translation projects Patient-Reported Outcomes version of
the Common Terminology Criteria for Adverse Events (PRO-CTCAE) and The Pa-
tient-Reported Outcomes Measurement Information System (PROMIS) will be high-
lighted.
Respiratory-Related Disorders – Cost Studies
PRS1
BUDGET IMPACT ANALYSIS OF FLUTICASONE FUROATE (FFNS) IN TREATMENT
OF ALLERGIC RHINITIS PATIENTS IN MEXICO
Rely K1, Salinas GE2, Anaya P3, Alexandre PK4
1CEAHealthTech, México, D.F., México, 2Hospital Infantil de México Federico Gómez, Secretaría
de Salud, México, D.F., México, 3GlaxoSmithKline México, México, D.F., México, 4Johns Hopkins
University, Baltimore, MD, USA OBJECTIVES: To estimate the 5-year projected impact
on the annual pharmacy budget for allergic rhinitis (AR) patients in Mexico.
METHODS: Mexican prevalence and treatment data for AR patients were obtained
from published and nonpublished sources. The model considered 2 scenarios—
without (pre) and with (post) FFNS. Market share data for corticosteroid treatment
options for AR pre-FFNS and in the first year post-FFNS were obtained from non-
published, real-world drug utilization data collected by GSK. Market shares for the
second until fifth years post- FFNS were forecasted by the study authors. Drug costs
were based on the Mexican Social Security Institute (IMSS). Wholesale Acquisition
Cost was accessed on March 2010. The results for each indication were analyzed
individually and summed to reflect the total impact of FFNS. Results were also
considered on a per member per month (PMPM) basis to examine the relative
impact on the plan. Sensitivity analyses were performed by varying several model
input parameters. RESULTS: The estimated prevalence of AR in 2010 was 10%. In
the year after its introduction, 60% of the AR population filled a prescription for
FFNS. The estimated total cost for AR treatment prior to introduction of FFNS was
$ 552 million and (532 to $ 384 million post FFNS. The incremental decrease in
pharmacy benefit cost was ($ 20 to $ 84 millions) in 2010 dollars. These reductions
translated to a medical care cost saving of $ 266 millions over 5 years.
CONCLUSIONS:Model results suggest that increasing the use of fluticasone furoate
decreases total budget costs due to decreased acquisition drug costs.
PRS2
COSTOS DE ATENCION MEDICA ATRIBUIBLES AL CONSUMO DE TABACO EN
MÉXICO
Reynales-Shigematsu L1, Quintana Carrillo R2
1Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México, 2Instituto Nacional de Salud
Pública, México, D.F., México
OBJECTIVOS: Estimar la carga económica, en términos de costos de atención
médica que las enfermedades atribuibles al consumo de tabaco representan para el
sistema de salud Mexicano. METODOLOGÍAS: La estimación del costo directo de
atención médica atribuible al tabaquismo se realizó con las enfermedades: CP, IAM,
EPOC y EVC, en 2009. Instituciones de salud participantes: institutos nacionales
(INNN, INCAN, INER e INCAR), Hospital Central Militar (HCM), Instituto de Seguri-
dad y Servicios Sociales de los Trabajadores del Estado (sólo incluye al CMN “20 de
Noviembre” y al HRZ “1°. de Octubre” del ISSSTE) e Instituto Mexicano del Seguro
Social (IMSS). El análisis de costos fue realizado desde la perspectiva del proveedor
de servicios, utilizando la metodología Cost of Illness, basada en la prevalencia así
como la creación de un panel de expertos multidisciplinario, que clasificó la aten-
ción médica: Ambulatoria, Urgencias, Hospitalización, Quirófano, Unidad de Cui-
dados Intensivos, Quimioterapia, Cuidados Paliativos y Radioterapia. Finalmente
empleamos la fracción atribuible por tabaco para estimar dichos costos. Los costos
están expresados en pesos mexicanos ($) y en dólares americanos (USD) del 2009.
RESULTADOS: Los costos institucionales de atención médica por tabaquismo as-
cendieron a $459,026,446.2 (35,131,636.3 USD); Institutos Nacionales, $92,016,175.0
(7,042,467.4 USD); HCM, $103,483,466.1 (7,920,117.7 USD); ISSSTE y $9,564,089,959.0
(731,988,608.4 USD); IMSS, respectivamente. Los costos nacionales por tabaquismo
oscilaron entre $30,213,184,046.5 (2,312,369,147.7 USD) y $44,484,500,278.1
(3,404,625,802.9 USD). El IAM y el CP fueron los más caros. CONCLUSIONES: Nues-
tros resultados muestran la elevada carga económica que representan para el sis-
tema de salud mexicano el tabaquismo y son evidencia científica sobre la magnitud
del problema. Como las enfermedades asociadas al tabaquismo son prevenibles,
una adecuada política de salud para el control del tabaco, produciría una reasig-
nación de los recursos económicos que actualmente se destinan al tratamiento de
las enfermedades provocadas por el tabaco hacia otros programas institucionales.
PRS3
COSTOS DE ATENCION MEDICA DE LA ENFERMEDAD PULMONAR
OBSTRUCTIVA CRONICA ATRIBUIBLES AL TABACO
Ramirez-Venegas A1, Quintana Carrillo R2, Sansores R1, Hernandez-Zenteno R1,
Reynales Shigematsu L2
1National Institute of Respiratory Diseases, México, D.F., México, 2National Institute of Public
Health, Cuernavaca, Morelos, México
OBJECTIVOS: Estimar los costos directos de atención médica de la Enfermedad
Pulmonar Obstructiva Crónica (EPOC) asociados al consumo de tabaco, en el Insti-
tuto Nacional de Enfermedades Respiratorias.METODOLOGÍAS:Durante el 2009 se
estimaron los costos directos de la EPOC de los pacientes que fueron atendidos en
el año 2008 en el Instituto. El análisis de costos se hizo desde la perspectiva del
proveedor de servicios, considerando el enfoque de la metodología Cost of Illness
(COI), basada en la prevalencia así como la creación de un panel de expertos mul-
tidisciplinario, que clasificó la atención médica en 4 eventos: Ambulatoria, Urgen-
cias, Hospitalización y Unidad de Cuidados Intensivos. Finalmente empleamos la
fracción atribuible por tabaco para estimar los costos por consumo de tabaco. El
costo además se estimo de acuerdo a la gravedad de la enfermedad con los criterios
GOLD. RESULTADOS: El costo anual de la EPOC atribuible al tabaco fue de $36
millones. El costo promedio por paciente, de acuerdo a GOLD fue de $30 mil; estadio
I, $37 mil; estadio II, $84 mil; estadio III y $288 mil; estadio IV. Entre más grave fue
la enfermedad, (III y IV) mayores costos resultaron. CONCLUSIONES: La evaluación
económica de los costos directos que ocasiona el EPOC debido al tabaquismo, con-
firma la gran carga económica que representan estos pacientes para el presupuesto
del INER y del sistema de salud mexicano. Estos resultados proveen suficiente
evidencia científica para apoyar la implementación de políticas del sector salud
relacionadas con el tabaco.
PRS4
ECONOMIC EVALUATION OF THE USE OF PALIVIZUMAB AS PROPHYLACTIC
TREATMENT FOR THE REDUCTION OF COMPLICATIONS ASSOCIATED WITH
RESPIRATORY SYNCYTIAL VIRUS IN PRE-TERM PATIENTS
Mayen-Herrera E1, Buesch K2, Cortina D3
1Abbott Laboratories de México, México, D.F. México, 2●●●, 3●●●
OBJECTIVES: To determine the incremental cost-effectiveness ratio (ICER) of the
use of palivizumab as prophylaxis for the reduction of complications associated
with respiratory syncytial virus (RSV) in pre-term patients29 weeks of gestational
age (WGA) under the Mexican public health sector perspective. METHODS: A cost-
utility model was developed based on a decision tree that evaluated both scenarios
of prophylaxis and no-prophylaxis. Epidemiological and cost data were obtained
from different Mexican sources such as the Mexican Institute of Social Security
(IMSS) by analysing birth rates. Clinical effectiveness was obtained from the inter-
national literature (Cardiac Synagis Study Group, The IMpact-RSV Study Group
MEDI-493 Study Group). Prophylaxis therapy consisted of 5 applications of palivi-
zumab during the winter season in Mexico. The dose scheme considered was 15
mg/kg. The effectiveness outcomes were quality adjusted life years (QALYs). Since
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the study was conducted under the public health perspective, only direct medical
costs associated with the RSV treatment were evaluated (hospitalization, emer-
gency room, drugs, and prophylaxis). For resource utilisation purposes, an expert
panel of paediatricians with experience in RSV infection was convened. Drug and
medical attention costs were discounted by using a 3% discount rate and are re-
ported in local currency. Acceptability curves of the probability of palivizumab to
be cost effective were calculated. The threshold included in the study for cost-
effectiveness comparisons, is the proposed by the World Health Organisation (3
times the gross domestic product per capita). RESULTS: The ICER per QALY for the
study group was MXN $219,150. The acceptability curves showed a 75% probability
of palivizumab to be cost effective when employing a 3 times GDP threshold.
CONCLUSIONS: The use of palivizumab represents a cost-effective alternative for
the prophylaxis of complications associated with RSV infection, under the public
health perspective in Mexico for patients 29 WGA.
PRS5
COST-EFFECTIVENESS OF VARENICLINE VS EXISTING SMOKING CESSATION
STRATEGIES IN DOMINICAN REPUBLIC USING THE BENESCO MODEL
Lutz M, Morales G, Cuesta G
Pfizer S.A., La Aurora, Heredia, Costa Rica
OBJECTIVES: In Dominican Republic, the economic burden of tobacco has not been
assessed. The aim of this study was to evaluate the cost-effectiveness of vareni-
cline compared to other existing strategies for smoking cessation within a 5-year
time horizon in an adult population cohort from Dominican Republic using the
healthcare payer’s perspective. METHODS: The Benefits of Smoking Cessation on
Outcomes (BENESCO) simulation model was used for an adult cohort in Dominican
Republic (n6,528,125). Smoking cessation therapies compared were: varenicline
(0.5 – 2 mg/day) versus bupropion (300 mg/day); nicotine replacement treatment
(NRT) (5-10 mg/day) and unaided cessation. Effectiveness measures were: Life-Year
gained (LYG) and quality-adjusted life-year gained (QALY’s). Resource use and
costs data were obtained from Dominican Republic’s Ministry of Health and Social
Security databases (2009). The model used a 3% discount rate for costs (expressed
in 2009 US dollars) and health outcomes. Probabilistic sensitivity analyses (PSA)
were conducted and acceptability curves were constructed. RESULTS: Varenicline
reduced smoking-related morbidity, mortality and healthcare costs. After 5 years,
mortality in the varenicline arm was reduced by 67, 86 and 163 deaths compared
with bupropion, NRT and unaided cessation, respectively. The net average cost per
additional quitter showed that varenicline was cost-saving against competing al-
ternatives. Varenicline exhibited 145, 188 and 355 more QALYs against Bupropion,
NRT and unaided cessation, respectively. Cost-effectiveness analyses showed that
varenicline was the dominant strategy. At a willingness-to-pay of US$8,000/QALY,
the probability that varenicline is cost-effective met 100%. PSA results support the
robustness of the findings. CONCLUSIONS: Smoking cessation therapy with va-
renicline is cost-saving in Dominican Republic. These results could help to reduce
the tobacco related disease burden and align cost-containment policies.
PRS6
COST-EFFECTIVENESS OF FLUTICASONE FUROATE COMPARED WITH
MOMETASONA FUROATE FOR THE PRIMARY TREATMENT OF ALLERGIC
RHINITIS PATIENTS
Rely K1, Alexandre PK2, Anaya P3, Salinas GE4
1CEAHealthTech, México, D.F., México, 2Johns Hopkins University, Baltimore, MD, USA,
3GlaxoSmithKline México, México, D.F., México, 4Hospital Infantil de México Federico Gómez,
Secretaría de Salud, México, D.F., México
OBJECTIVES: To evaluate the cost-effectiveness of fluticasone furoate vs. mome-
tasone furoate in the treatment of ocular symptoms in allergic rhinitis patients in
Mexico. METHODS: A decision-analytic model was developed to estimate the cost-
effectiveness of fluticasone furoate versus mometasone furoate. Patients initiated
on treatment either completed initial therapy or switched to second line therapy
due to non-response. Probability of a switch and resource use was based on expert
panel and literature. Costs were based on local drug acquisition costs, local cost
estimates for outpatient and hospitalization. Effectiveness was defined as the net
improvement in Total Ocular Symptom Score (TOSS) at 12 weeks from Keith PK.
2009 study. The analysis was carried out from the perspective of the Mexican
health care system and all costs are reported in 2010 US dollars. RESULTS: The
corresponding health effects were 0.47 net improvement TOSS for fluticaone fu-
roate and 0.31 for mometasone furoate regimen. The mean total cost of the fluti-
caone furoate regimen was $ 627 compared with $ 827 for the furoate mometasone
regimen. Treatment with fluticasone furoate compared to treatment with mome-
tasone furoate was less costly and resulted in a greater net improvement of TOSS.
Probabilistic sensitivity analyses demonstrated that the cost savings observed
were maintained over a wide range of alternative values for costs and resource
utilization. CONCLUSIONS: Cost-effectiveness analysis indicated the dominance
of fluticasone furoate over mometasone furoate because of both lower costs and
greater efficacy. Cost savings with fluticasone furoate were attributable to lower
drug acquisition costs. In addition, a net improvement in ocular symptoms may be
expected in allergic rhinitis patients.
PRS7
ESTUDIO DE COSTO-EFECTIVIDAD DE BECLOMETASONA VS CICLESONIDA
COMO MEDICAMENTOS CONTROLADORES EN EL MANEJO DEL ASMA EN
PACIENTES QUE ASISTEN A CONSULTA EXTERNA DE NEUMOLOGÍA
PEDIÁTRICA EN EL HOSPITAL UNIVERSITARIO CLÍNICA SAN RAFAEL DE
BOGOTÁ COLOMBIA, JULIO A DICIEMBRE 2010
Hinestrosa F1, Pedraza AM2
1Grünenthal Colombiana S.A., Bogotá, Colombia, 2Hospital San Rafael, Bogotá, Colombia
OBJECTIVOS:Desarrollar un estudio de costo-efectividad que compare Ciclesonida
con Beclometasona en el control del asma. METODOLOGÍAS: Estudio Costo-Efec-
tividad, de cohortes, observacional, analítico, con información recolectada pro-
spectivamente, realizado desde la perspectiva institucional, incluyó pacientes
pediátricos con diagnóstico de asma no controlada admitidos durante Julio de 2010
los que recibieron Ciclesonida o Beclometasona como único medicamento contro-
lador. Se realizó seguimiento por 6 meses, basados en datos reportados por la
literatura se utilizó el porcentaje de pacientes libres de crisis asmáticas como vari-
able para el cálculo del tamaño muestral, la muestra necesaria fué de 20 pacientes
por cada alternativa, se incluyeron 94 pacientes con edades entre los 1 y 15 años, 47
recibieron Beclometasona y 47 Ciclesonida. La asignación fue de manera aleatoria.
La variable primaria de efectividad fue definida como el porcentaje de pacientes
libres de crisis durante el periodo de estudio, se definieron como variables genera-
doras de costo uso de medicamentos y estancia hospitalaria. Se calculó la razón
costo-efectividad incremental y se realizó un modelo mediante un árbol de
decisión. RESULTADOS: 17 pacientes estuvieron libres de crisis en el grupo de
Beclometasona, los costos de utilización de medicamentos en este grupo fueron de
$7255.564 pesos colombianos, los costos de hospitalización se calcularon en
$38,568.200, los costos totales ascendieron a $45,823.764 ($25,188.67 dólares). En el
grupo de Ciclesonida, 45 pacientes estuvieron libres de crisis, los costos por uti-
lización de medicamentos fueron de $14,982.172, los costos derivados de hospital-
ización se calcularon en $92,200, los costos totales alcanzaron los $15,074.372
($8291.73 dólares). La razón costo-efectividad incremental de Beclometasona ver-
sus Ciclesonida fue de -1’098.192. CONCLUSIONES: Al utilizar Ciclesonida el hos-
pital encuentra ahorros de $1098.192 pesos por cada paciente libre de crisis, desde
la perspectiva del hospital, el manejar un paciente con Beclometasona representa
un costo adicional de $1,098.192 que se podrían ahorrar si el paciente fuese mane-
jado con Ciclesonida.
PRS8
COST-EFFECTIVENESS OF AN AMBULATORY PROGRAM OF PULMONARY
REHABILITATION FOLLOWING ACUTE EXACERBATIONS OF COPD IN COLOMBIA
Giraldo LF, Brito KP, Rodriguez P
Universidad de La Sabana, Chia, Cundinamarca, Colombia
OBJECTIVES: To evaluate the economic benefits of an 8 week Ambulatory Pulmo-
nary Rehabilitation Program (PR) plus GOLD based standard treatment (ST) vs. ST
without PR of COPD patients after an acute exacerbation of the disease in the
Colombian Health Care System (CHCS). METHODS: Direct costs of ST and of PR
were calculated according to tertiary level university hospital’s registries during
one year and CHCS’s drugs prices; these costs and QALY were estimated for one
year by a Markov chain model based on Seymour’s study (Thorax, 2010) findings of
health care utilization and probability of death. Univariate sensitivity and proba-
bilistic analysis were performed by Monte Carlo method.RESULTS: Following acute
exacerbation of COPD the annual cost of PR plus ST was COL$ 4,594,407,00 (US$
2,483.46) vs. an annual cost of ST without PR of COL$ 9,124,326.00 (US$ 4,932.07).
QALY of PR plus ST patients: 0.86577; QALY of ST without PR: 0.852979. Mean
cost-effectiveness of PR plus ST: COL$5,306,729.00 (US$ 2,868.50) per QALY, cost-
effectiveness of ST without PR:$10,697,014.00 (US$ 5,782.17) per QALY. There was
absolute dominance of PR plus ST vs. ST without PR in all scenarios. In the sensi-
tivity analysis the absolute dominance is maintained for any cost of PR program
COL$ 5,302,428.00 (US$ 2.866,18). CONCLUSIONS: Global costs of Pulmonary Reha-
bilitation plus Standard Treatment are much lower than Standard Treatment with-
out Pulmonary Rehabilitation for patients after an acute exacerbation of COPD.
Pulmonary Rehabilitation is a highly cost-effective treatment for these patients in
the CHCS and probably in many other countries with similar socio-economic level,
specially of Latin America.
Respiratory-Related Disorders – Patient-Reported Outcomes & Preference-Based
Studies
PRS9
DISPONIBILIDAD A PAGAR POR UN METODO EFECTIVO PARA DEJAR DE FUMAR:
EVIDENCIAS A PARTIR DE LA ENCUESTA GLOBAL DE TABAQUISMO EN
ADULTOS MÉXICO 2009
Heredia I, Serván E, Reynales LM, Bautista S
Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México
OBJECTIVOS: Estimar la máxima disponibilidad a pagar (DAP) por un tratamiento
efectivo de cesación tabáquica entre fumadores mexicanos e identificar los facto-
res sociodemográficos, de la historia de fumador y de su entorno asociados a esta
valoración. METODOLOGÍAS: Se realizó un estudio observacional de tipo transver-
sal. La muestra de análisis estuvo constituida por 777 fumadores que participaron
en la Encuesta Global de Tabaquismo en Adultos, México 2009. Se realizó un análi-
sis descriptivo y de asociación estadística que permitió caracterizar a los fuma-
dores y su DAP con base en variables socioeconómicas, demográficas, de su historia
de tabaquismo y de su entorno. RESULTADOS: El 74.4% de los fumadores eran del
sexo masculino, 51.4% consumía cigarrillos con una frecuencia diaria. Los fuma-
dores tenían más de 15 años fumando, 58.6% había realizado intentos previos de
cesación y alrededor del 10% conocía de la existencia de centros de ayuda para
dejar de fumar. En promedio, la DAP por un método efectivo de cesación fue $2573
pesos mexicanos. En los hombres, la DAP fue 2056 pesos menor que en las mujeres.
A mayor educación y mayor nivel socioeconómico (NSE), la DAP de los fumadores
aumentó en todos los modelos estimados. CONCLUSIONES: Las estimaciones del
presente estudio sugieren que los fumadores mexicanos que desean dejar de fu-
mar revelan, en términos monetarios, una alta valoración por un método de ce-
sación efectivo. Los fumadores del sexo masculino muestran un comportamiento
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